Podcasts about Attribution

The party returns to Fort Trand to conduct the kingdom's business and investigate the newly discovered Cradle of Lamashtu.WebsiteDiscordTwitterPathfinder Second Edition and the Kingmaker Adventure Path are published by Paizo."Take the Lead" and other featured music were composed by Kevin MacLeod and licensed under Creative Commons by: Attribution 4.0 License.All ambiances were composed by Michael Ghelfi Studios.The Zero Check are committed to providing an inclusive and respectful experience to all listeners, but we also recognize and acknowledge that we are limited by our individual frames of reference. If we misstep, please let us know. Email all feedback to feedback@zerocheckpodcast.com.Thank you for listening to The Zero Check. Send us a text

"We proposed a concept to the American Society of Clinical Oncology (ASCO), recognizing that extravasation management requires significant interdisciplinary collaboration and rapid action. There can occasionally be uncertainty or lack of clear guidance when an extravasation event occurs, and our objective was to look at this evidence with the expert panel to create a resource to support oncology teams overall. We hope that the guideline can help mitigate harm and improve patient outcomes," Caroline Clark, MSN, APRN, AGCNS-BC, OCN®, EBP-C, director of guidelines and quality at ONS, told Chelsea Backler, MSN, APRN, AGCNS-BC, AOCNS®, VA-BC, oncology clinical specialist at ONS, during a conversation about the ONS/ASCO Guideline on the Management of Antineoplastic Extravasation. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 2, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the management of antineoplastic extravasation. Episode Notes  Complete this evaluation for free NCPD. ONS/ASCO Guideline on the Management of Antineoplastic Extravasation ONS Podcast™ episodes: Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 335: Ultrasound-Guided IV Placement in the Oncology Setting Episode 145: Administer Taxane Chemotherapies With Confidence Episode 127: Reduce and Manage Extravasations When Administering Cancer Treatments ONS Voice articles: Access Devices and Central Lines: New Evidence and Innovations Are Changing Practice, but Individual Patient Needs Always Come First New Extravasation Guidelines Provide Recommendations for Protecting Patients and Standardizing Care Standardizing Venous Access Assessment and Validating Safe Chemo Administration Drastically Lowers Rates of Adverse Venous Events This Organization's Program Trains Non-Oncology Nurses to Deliver Antineoplastic Agents Safely ONS books: Access Device Guidelines: Recommendations for Nursing Practice and Education (fourth edition) Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) ONS courses: Complications of Vascular Access Devices (VAD) and IV Therapy ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS Oncology Treatment Modalities Clinical Journal of Oncology Nursing articles: Chemotherapy Extravasation: Incidence of and Factors Associated With Events in a Community Cancer Center Standardized Venous Access Assessment and Safe Chemotherapy Administration to Reduce Adverse Venous Events Oncology Nursing Forum article: Management of Extravasation of Antineoplastic Agents in Patients Undergoing Treatment for Cancer: A Systematic Review ONS huddle cards: Antineoplastic Administration Chemotherapy Immunotherapy Implanted Venous Port ONS position statements: Administration (Infusion and Injection) of Antineoplastic Therapies in the Home Education of the Nurse Who Administers and Cares for the Individual Receiving Antineoplastic Therapies ONS Guidelines™ for Extravasation Management ONS Oncologic Emergencies Learning Library ONS/ASCO Algorithm on the Management of Antineoplastic Extravasation of Vesicant or Irritant With Vesicant Properties in Adults American Society of Clinical Oncology (ASCO) Podcast: Management of Antineoplastic Extravasation: ONS-ASCO Guideline To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The focus of this guideline was specifically on intravenous antineoplastic extravasation or when a vesicant or an irritant with vesicant properties leaks out of the vascular space. This can cause an injury to the patient that's influenced by several factors including the specific drug that was involved in the extravasation, whether it was DNA binding, how much extravasated, the affected area, and individual patient characteristics." TS 1:48 "The panel identified and ranked outcomes that mattered most with extravasation. Not surprising, one of the first was tissue necrosis. Like, 'How are we going to prevent tissue necrosis and preserve tissue?' The next were pain, quality of life, delays in cancer treatment: How is an extravasation going to delay cancer treatment that's vital to the patient? Is an extravasation also going to result in hospitalization or additional surgical interventions that would be burdensome to the patient? ... We had a systematic review team that then went in and summarized the data, and the panel applied the grading of recommendations, assessment, development, and evaluation (GRADE) criteria, grading quality of evidence and weighing factors like patient preferences, cost, and feasibility of an intervention. From there, they developed their recommendations." TS 7:35 "The panel, from the onset, wanted to make sure we had something visual for our readers to reference. They combined evidence from the systematic review, other scholarly sources, and their real-world clinical experience to make this one-page supplementary algorithm. They wanted it to be comprehensive and easy to follow, and they included not only those acute management steps but also guidance on 'How do I document this and what are the objective and subjective assessment factors to look at? What am I going to tell the patient?' In practice, for use of that, I would compare it to your current processes and identify any gaps to inform policies in your individual organizations." TS 16:34 "The guidelines don't take place of clinician expertise; they're not intended to cover every situation, but a situation that keeps coming up that we should talk about as a limitation, is we're seeing these case reports of tissue injury with antibody–drug conjugate extravasation. There's still not enough evidence to inform care around the use of antidotes with those agents, so this still needs to be addressed on a case-by-case basis. We still need publication of those case studies, what was done, and outcomes to help inform direction." TS 19:24 "Beyond the acute management is to ensure thorough documentation regarding extravasation. Whether you're on electronic documentation or on paper, are the prompts there for the nurse to capture all of the factors that should be captured regarding that extravasation? The size, the measurement, the patient's complaints. Is there redness? Things like that. And then within the teams, everyone should know where to find that initial extravasation assessment so that later on, if they're in a different clinic, they have something to go by to see how the extravasation is healing or progressing. ... I think there's an importance here, too, to our novice oncology nurses and their preceptors. This could be anxiety-provoking for the whole team and the patient, so we want to increase confidence in management. So, I think using these resources for onboarding novice oncology nurses is important." TS 22:34

In this episode of "The Free Lawyer," host Gary interviews Bo Royal, a former Fortune 500 marketing executive who successfully transitioned to legal marketing. Bo shares how he quadrupled online case volume at a major Philadelphia injury law firm by implementing data-driven strategies and shifting focus from traditional to digital channels. He discusses the importance of tracking, intake systems, and operational readiness for law firms, and explains how his company, Pareto Legal, helps firms build robust case pipelines. The episode offers practical insights for maximizing marketing efficiency and leveraging digital tools to drive sustainable law firm growth.Bo Royal is a former Fortune 500 agency exec who spent over a decade scaling online revenues for iconic brands like Calvin Klein, GNC, Sallie Mae, and Kate Spade New York. After leaving the corporate grind, he took the helm at a top Philadelphia injury law firm, supercharging its online case volume by fourfold through data-driven decisions and relentless focus. His journey from high-stakes agency work to legal marketing quickly established him as an industry expert with a knack for results.Now, as an advisory board member at that very firm—thriving with eight-figure revenues and 12 office locations across Pennsylvania—Bo drives innovation at Pareto Legal. His team empowers small and medium-sized law firms to secure seven- to eight-figure case pipelines by leveraging real-world experience and smart digital strategies. When he's not optimizing campaigns, Bo shares his marketing insights on podcasts and uses his success to give back to the community.Bo's Transition from Corporate to Legal Marketing (00:02:05) Initial Surprises in Legal Marketing (00:03:59) Diagnosing and Transforming the Law Firm's Marketing (00:05:49) Shifting from Traditional to Digital Marketing (00:08:35)Earned vs. Unearned Case Pipeline (00:10:41) OTT and Modern Advertising Explained (00:12:13) Importance of Data-Driven Decision Making (00:13:19)Implementing a Culture of Data and Change (00:15:45) Pareto Legal's Differentiated Approach (00:18:22) Assessing Firm Readiness for Digital Marketing (00:22:06) Vanity Metrics vs. Real Results (00:25:39) Holistic Marketing Efficiency and Attribution (00:27:52) The Hawthorne Effect and Tracking Benefits (00:32:06) Current Trends and AI in Legal Marketing (00:33:49)You can find The Free Lawyer Assessment here- https://www.garymiles.net/the-free-lawyer-assessmentWould you like to learn what it looks like to become a truly Free Lawyer? You can schedule a complimentary call here: https://calendly.com/garymiles-successcoach/one-one-discovery-callWould you like to learn more about Breaking Free or order your copy? https://www.garymiles.net/break-free

Hosts Kevin Schwaller and Ema Sasic are ringing in the new year with a look back at 2025 in film and ranking their top 10 favorite movies of the year. Let's see what 2026 brings!Disclaimer:Copyright notice:(Intro/outro) She's The Greatest Dancer by Ryan Andersen is licensed under a Attribution-NonCommercial License. https://freemusicarchive.org/music/Ryan_Andersen/MORE/Shes_The_Greatest_Dancer?fbclid=IwAR1TDCO9eT6TxmDrTaJr9HRQVk2gUu00cNXeG8oik3avXVEhbSGqsqUfLkoCopyright notice:(Break) Extremely Tik-tok compatible for slow videos by Lundstroem is licensed under a Attribution 4.0 International License. https://freemusicarchive.org/music/lundstroem/the-happiest-songs/extremely-tik-tok-compatible-for-slow-videos/

Episode 23- Happy New Years! An actual play, tabletop role-playing game that uses the Pathfinder 1E rule-set. The epic story follows the brave players through a unique dark fantasy world. The Heroes trials and tribulations will have them brought face to face with demons, devils, angry spirits, the occult, and more. The story takes place in the dark fantasy world of Mel'Herron. Our heroes are brought together by mysterious circumstances leaving them with more questions than answers. An ever-present dark force seems to be lurking in the shadows seeking the party for reasons they must figure out or be swept up by the coming storm. Please like and follow !!! =) Marty is the Dungeon Master, Bobby plays Uri, Wes plays Rein, Derek plays Solaris, Morris play Lirium, Marcus plays Torad Follow us on Twitter: @dicebargaming1    Facebook: The Dice Bar Gaming Podcast Music by: https://www.fesliyanstudios.com Scott Buckley  www.scottbuckley.com.au. Kevin MacLeod Link: https://incompetech.filmmusic.io/song/5048-stay-the-course License: https://filmmusic.io/standard-license. Paid license from: www.epidemicsound.com March of Midnight by Scott Buckley | www.scottbuckley.com.au Music promoted by https://www.chosic.com Attribution 4.0 International (CC BY 4.0) https://creativecommons.org/licenses/by/4.0/ Unseen Horrors Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 3.0 License http://creativecommons.org/licenses/by/3.0/ Music promoted by https://www.chosic.com/ For world info- https://www.worldanvil.com/w/mel-herron-bruehawk Friends of the podcast: Bored Online? Board Offline!- https://www.youtube.com/channel/UCVmlVsZVlruYWnIYd42iBhw Game Knight Hero Podcast- https://podcasts.apple.com/us/podcast/game-knight-heroes/id1552887060 Deadlands by Kerri Smith- https://www.youtube.com/channel/UCAVrPUutK3IvxLWDKaN3UgQ **Episodes contain adult content. “a mature Podcast”**

Welcome to another edition of Bettin N Boozin on the HHH Racing Podcast! This episode we move back to South Florida for Ep 162 to preview the Late Pick5 at Gulfstream Park for 01/03/26 brought to you by TwinSpires! Who do we think wins? Find out in this episode!Come for the handicapping, stay for a drink!It's a great day to make some money, we are always Boozin N Not Losin! Stay tuned for GREAT ANALYSIS and see you in the LIVE CHAT!Please Like, Subscribe and comment below the video player your opinions, we would love to hear from you and respond to every one!__________________________________________________________________NORMAL PODCAST SCHEDULE:Tuesday Night @9:30pm EDT: Pacific Horseplayers with Noah, Ryan and JacksonWednesday Night @8pm EDT: Bettin N Boozin with Kyle, Patrick and Charlie (Noah) Thursday Night @8pm EDT: Picks and Ponies with Howard, Pete and Paul(MORE COULD BE ADDED AT ANY TIME, PLEASE SUBSCRIBE AND HIT THE NOTIFICATION BELL TO BE NOTIFIED OF ALL LIVESTREAMS/VIDEOS!)__________________________________________________________________Go to our website: https://www.hhhracingpodcast.com__________________________________________________________________Podcast Twitter/X: @hhhracingpodHost:Kyle Roscoe: X - @APRoscoeKCo-Hosts:Andrew Rdesinski: X - @phillyboy415Patrick Kuenzel: X - @PatrickKuenzelCharlie Freeman: X - @CFREE316_________________________________________________________________Horse Racing Promotions: Subscribe to the excellent, informative, AFFORDABLE and profitable "Power Picks" Tip Sheet! Please go to: www.patreon.com/hhhracingpodcast Fantastic ABC P4 and P5 grids, along with Spot Plays and Price Plays provided that currently has an ROI around $2.15 (national average is $1.60). Picks arrive via email every Sat. morning for that day's races. Purchase your Power Picks NOW and make 2024 your best handicapping year ever! www.patreon.com/hhhracingpodcast__________________________________________________________Bettin N Boozin Logo by Erik Morgan (Instagram @erik_mgn10)__________________________________________________________Intro Music:Superepic by Alexander Nakarada | https://creatorchords.com/Music promoted by https://www.chosic.com/free-music/all/Attribution 4.0 International (CC BY 4.0)https://creativecommons.org/licenses/...___________________________________________________________Horse Racing Intro Background Video graciously provided by @Fastec ImagingLink to video: https://www.youtube.com/watch?v=UfuI_TiKDYI&t=32s___________________________________________________________LINK TO A GREAT HORSE RACING OWNERSHIP OPPORTUNITY WITH CROWNS WAY RACING: https://sites.google.com/view/crowns-way-racing___________________________________________________________LINK TO SIGN UP TO BETUS -- (USE CODE RACING3H WHEN DEPOSITING MONEY)https://www.betus.com.pa___________________________________________________________#horseracing #horseracingtips #GulfstreamPark #GulfstreamParkPicks

Attribution des permis by-catch – Arvin Boolell : « Les activistes ont aussi le droit de postuler. Il n'y a pas de monopole dans ce secteur » by TOPFM MAURITIUS

In dieser Folge blicken wir ehrlich und nüchtern auf das Bitcoin-Jahr 2025 zurück. Wir sprechen darüber, warum viele Erwartungen – insbesondere rund um Preisentwicklung und Bullrun – nicht erfüllt wurden und weshalb nahezu alle Prognosen, auch unsere eigenen, danebenlagen. Der ausbleibende Hype, fehlendes Retail-Interesse sowie politische und regulatorische Themen standen dieses Jahr stärker im Fokus als Bitcoin selbst. Außerdem ordnen wir Entwicklungen wie die MiCA-Regulierung, den Einfluss von Staaten und Institutionen und die Frage nach dem Ende klassischer Bitcoin-Zyklen ein. Zum Abschluss geben wir einen vorsichtigen Ausblick auf 2026 und sprechen darüber, wie es mit dem Podcast weitergeht.

Episode 22- Happy Holiday friends! An actual play, tabletop role-playing game that uses the Pathfinder 1E rule-set. The epic story follows the brave players through a unique dark fantasy world. The Heroes trials and tribulations will have them brought face to face with demons, devils, angry spirits, the occult, and more. The story takes place in the dark fantasy world of Mel'Herron. Our heroes are brought together by mysterious circumstances leaving them with more questions than answers. An ever-present dark force seems to be lurking in the shadows seeking the party for reasons they must figure out or be swept up by the coming storm. Please like and follow !!! =) Marty is the Dungeon Master, Bobby plays Uri, Wes plays Rein, Derek plays Solaris, Morris play Lirium, Marcus plays Torad Follow us on Twitter: @dicebargaming1    Facebook: The Dice Bar Gaming Podcast Music by: https://www.fesliyanstudios.com Scott Buckley  www.scottbuckley.com.au. Kevin MacLeod Link: https://incompetech.filmmusic.io/song/5048-stay-the-course License: https://filmmusic.io/standard-license. Paid license from: www.epidemicsound.com March of Midnight by Scott Buckley | www.scottbuckley.com.au Music promoted by https://www.chosic.com Attribution 4.0 International (CC BY 4.0) https://creativecommons.org/licenses/by/4.0/ Unseen Horrors Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 3.0 License http://creativecommons.org/licenses/by/3.0/ Music promoted by https://www.chosic.com/ For world info- https://www.worldanvil.com/w/mel-herron-bruehawk Friends of the podcast: Bored Online? Board Offline!- https://www.youtube.com/channel/UCVmlVsZVlruYWnIYd42iBhw Game Knight Hero Podcast- https://podcasts.apple.com/us/podcast/game-knight-heroes/id1552887060 Deadlands by Kerri Smith- https://www.youtube.com/channel/UCAVrPUutK3IvxLWDKaN3UgQ **Episodes contain adult content. “a mature Podcast”**

"They [monoclonal antibodies] are able to cause tumor cell death by binding to and blocking to necessary growth factor signaling pathways for tumor cell survival. That's going to be dependent on the target of the antibody, but I'll give an example of epidermal growth factor, or EGFR. This is overexpressed in several different kinds of cancers where activation of this growth factor increases the amount of proliferation and migration of cancer cells. So, if we bind to it and block to it, then that would help halt these pathways and stop cancer cell growth," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about monoclonal antibodies. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) (including 45 minutes of pharmacotherapeutic content) by listening to the full recording and completing an evaluation at courses.ons.org by December 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of monoclonal antibodies in the treatment of cancer.  Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 383: Pharmacology 101: Bispecific Antibodies Episode 375: Pharmacology 101: VEGF Inhibitors Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors ONS Voice articles: An Oncology Nursing Overview of Biosimilars Make Subcutaneous Administration More Comfortable for Your Patients Oncology Nurses' Role in Translating Biomarker Testing Results Reduce Chair Time by as Much as 16 Minutes by Priming IVs With Drug Shorter Administration Times Still Require High-Acuity Care The Names of Targeted Therapies Give Clues to How They Work ONS Voice drug reference sheets: Datopotamab deruxtecan-dlnk Enfortumab vedotin Margetuximab-cmkb Mirvetuximab soravtansine-gynx Nivolumab and hyaluronidase-nvhy Nivolumab and relatlimab-rmbw Pembrolizumab and berahyaluronidase alfa-pmph Retifanlimab-dlwr ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial Management of Immunotherapy Infusion Reactions Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oncology Nursing Forum articles: Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer Depressive Symptoms and Quality of Life Associated With the Use of Monoclonal Antibodies in Breast Cancer Treatment ONS huddle cards: Bispecifics Checkpoint Inhibitors Monoclonal Antibodies Other ONS resources: Biomarker Database Bispecific Antibodies video Patient Education Sheets Antibodies article: A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy Cureus article:  A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach Association of Cancer Care Centers (ACCC) homepage Cancer Immunology, Immunotherapy article: Therapeutic Antibodies in Oncology: An Immunopharmacological Overview Drugs@FDA package inserts Future Oncology article: Biosimilars: What the Oncologist Should Know Hematology/Oncology Pharmacy Association homepage National Comprehensive Cancer Network homepage Network for Collaborative Oncology Development and Advancement (NCODA) subcutaneous therapy article Oncolink: Side Effects of Immunotherapy World Health Organization: New International Nonproprietary Names (INN) Monoclonal Antibody Nomenclature Scheme To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Prior to monoclonal antibodies, all we really had were these toxic chemotherapies or toxic radiation, so it was recognized how great it would be if we could have a treatment that was much more specific to the tumor cells and have agents that have less toxicities. These advancements in monoclonal antibody production began in the 1980s. ... Eventually, we had the first monoclonal antibody that was approved by the U.S. Food and Drug Administration (FDA) for an oncologic indication, rituximab." TS 4:14  "Nowadays, we do have treatments that are also considered tumor-agnostic. This is when a patient has a certain biomarker, then that treatment can be given and FDA approval was given, regardless what type of tumor the patient has. We typically see these kinds of tumor-agnostic therapies more so in patients who have recurrent or advanced diseases in solid tumors. One monoclonal antibody example that comes to mind is dostarlimab. That's a checkpoint inhibitor that's approved for patients who are deficient in mismatch repair mechanism." TS 23:48 "Our immune system constantly has this surveillance system and it's able to recognize foreign pathogens, abnormal cells, and even precancerous cells. And they're able to eliminate them before they become cancerous. But on the flip side, one of the regulatory mechanisms that we have so our immune system doesn't attack itself is the presence of checkpoints. When these checkpoints bind to their ligands, this can then act as an off switch so that, again, our immune system is not going to attack itself. But then the tumor cells can take advantage of this and actually use this mechanism to evade the immune system. So, when we're giving a checkpoint inhibitor, now we're removing that off switch. As a consequence, common adverse effects can include things like immune mediated adverse events. These most commonly affect the skin, gastrointestinal tract, and liver. Essentially, this can cause any '-itis' you can think of." TS 26:36 "Looking at strategies to prevent infusion reactions, one example is the use of premedication. If premedication is recommended, this typically includes any combination of antipyretics, which is typically acetaminophen. Antihistamine, which is typically an H1 antagonist like diphenhydramine. Although, there could be cases where we want to substitute this agent because maybe the patient has been tolerating therapy okay, and they're having a lot of side effects. So, we might use a second-generation antihistamine in some cases. The premedication may be given with or without some kind of steroid, whether that's methylprednisolone, hydrocortisone, or dexamethasone." TS 29:53 "We tend to think of monoclonal antibody usage to be primary oncology, but that's not really the case. The first monoclonal antibodies that were developed were not for oncologic indications, they were for transplant indication for cardiac indication. So, they're really diversely utilized across all specialties and medicines. We have monoclonal antibodies for hyperlipidemia, for neurology, for rheumatology, so the uses are so very expansive across all specialties." TS 41:01

1:17:32 – Birmingham Pizza of the Sea Review – Holiday Edition – with Chad Bowers and Mike Boody. License for this track: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) (https://creativecommons.org/licenses/by-nc-nd/4.0/). Attribution: by Chad Bowers – more info at titfos.tumblr.com or onsug.com.

サイクリング関連の気になるニュースの話をするNEWS UPDATE

Our lead story: The National Children's Chiefs Commission and the First Nations Child and Family Caring Society claim their plan for long-term First Nations child welfare reform is more thorough than the federal government's. NOTE: APTN NEWS BRIEF WILL BE ON HIATUS OVER THE HOLIDAYS, RETURNING TUESDAY, JANUARY 6, 2026. MUSIC: 'Abundance' by 1000 Handz is licensed under an Attribution 4.0 International License.

In this episode of the AdTechGod Pod, guests Aaron Goldman (Mediaocean), Tony Marlow (LG Ads), and Jackelyn Keller (Jackwell Partners) reflect on the past year in advertising, the impact of AI, and the trends shaping the future. The conversation covers everything from weird meetings in 2025 to the overhyped nature of AI and retail media. The guests share insights on the importance of understanding data, the challenges of attribution, and the need for creativity in marketing. The episode concludes with a rapid-fire round of questions, revealing personal opinions and humorous takes on the industry. Takeaways AI has significantly influenced all industries, not just advertising. Naming and branding can lead to intense discussions in meetings. AI-powered solutions are often overhyped in the industry. Retail media networks may struggle to survive without scale. Attribution methods in advertising are complex and often debated. Predictions in the industry can be unnecessary and overdone. Creative optimization is essential for effective marketing campaigns. Understanding data is crucial for marketers to make informed decisions. The future of advertising may involve more interactive and engaging ad formats. The importance of chilling out about industry drama and focusing on collaboration. Chapters 00:00 Welcome and ugly sweaters 03:40 50 Cent and NewFront prep 06:20 AI hype vs reality 08:45 Curation and other buzzwords 12:10 AdCP and why it is hard 14:30 Creative optimization A/B to A-Z 17:45 Ads inside AI chat experiences 18:45 Regifting trends, retail media, and clean rooms 22:10 Agentic commerce debate 25:40 What the industry should chill about 29:30 Rapid-fire questions 36:00 Wrap-up and holiday sign-off Learn more about your ad choices. Visit megaphone.fm/adchoices

O podcast de hoje é a grande celebração do trabalho de diferentes mulheres na indústria do cinema e da televisão desse ano: o Troféu Alice 2025, nosso prêmio de preferidos do ano. O programa é apresentado por Isabel Wittmann e Camila Henriques.Votaram, em ordem alfabética:Barbara Demerov: Site | LetterboxdBeatriz Saldanha: Site | LetterboxdCamila Henriques: Site | LetterboxdCarissa Vieira: Site | LetterboxdCarla Oliveira: Site | LetterboxdCarol Ballan: Site | Letterboxd Cecília Barroso: Site | Letterboxd Gabriela Larocca: Site | LetterboxdIeda Marcondes: Site | Letterboxd Isabel Wittmann: Site | Letterboxd Júlia Gavillan: Site | LetterboxdLarissa Paiva Maia: Site | Letterboxd Ligia Ferraz: Site | Letterboxd Maitê Mendonça: Site | LetterboxdMari Dertoni: Site | LetterboxdNatália Bocanera: Site | Letterboxd Pamela Eurídice: Site | LetterboxdRaíssa Basílio: Site | LetterboxdRaíssa Ferreira: Site | Letterboxd Stephania Amaral: Site | Letterboxd Tati Regis: Site | Letterboxd além de nossa audiência.A lista com todos os filmes premiados e votados pode ser conferida aqui.Feedback: contato@feitoporelas.com.brFeed | Bluesky | Instagram | Letterboxd | TelegramApresentação: Isabel Wittmann e Camila HenriquesPesquisa, pauta e roteiro: Isabel WittmannProdução do programa, edição de áudio, edição de vídeo e de vídeo e arte da capa: Isabel WittmannVinheta: Felipe Ayres Locução da vinheta: Deborah Garcia (deh.gbf@gmail.com)Música de encerramento: Bad Ideas - Silent Film Dark de Kevin MacLeod está licenciada sob uma licença Creative Commons, Attribution, Origem, Artista.Apoie nosso financiamento coletivo.Pix: contato@feitoporelas.com.brReferências completas no site: https://feitoporelas.com.br/feito-por-elas-209-trofeu-alice-2025-melhores-do-ano/

In dieser Folge sprechen wir mit dem Geldökonomen Prof. Dr. Stefan Kooths vom Kiel Institut für Weltwirtschaft über die Grundlagen unseres Geldsystems, die Rolle von Zentralbanken und Staaten sowie die strukturellen Anreize hinter Inflation. Wir diskutieren, warum Geldschöpfung ein enormes Privileg ist, wen Inflation tatsächlich trifft und weshalb stabile Währungen für eine funktionierende Marktwirtschaft entscheidend sind. Außerdem geht es um Währungswettbewerb, die Idee von Hayek, die Rolle der EZB und darum, welche Bedeutung Bitcoin als staatsfreies Geld in diesem Kontext haben kann.

Featured on Bourgeois: Baby Uh-u-Hoo and the First Halloween - Tytarchuk Fedir Alexandrovych - narrated by Bradford Lundon Man's Best Friend? by David Dumouriez - narrated by Jimbo Bookmarking - by Harris Coverley New Tricks - by Chuck McKenzie Our Audio License AntipodeanSF Radio Show by Ion Newcombe is licensed under CC BY-NC-ND 4.0 Featured Music Spooky Halloween instrumental | Halloween by Alex-Productions is licensed under a Attribution-NonCommercial 4.0 International License. Human Being Being Human by Jon Shuemaker is licensed under a Attribution-NonCommercial 4.0 International License. Library Loudness by strond is licensed under a Attribution-NonCommercial-ShareAlike 4.0 International License. Spirit Horror by Universfield is licensed under a Attribution 4.0 International License. Intro & Outro Music Celestial Navigation by Blue Dot Sessions is licensed under a Attribution-NonCommercial License

In this final Nicaragua episode, Laura travels to Granada the way so many locals do—by chicken bus. These colorful, chaotic former U.S. school buses are an experience in themselves, and the journey from Ometepe to Granada is filled with market noise, snack vendors, seat strategy, and a healthy dose of travel nostalgia.Once in Granada, Laura wanders the relaxed colonial streets of one of the oldest cities in the Americas, founded in 1524 and shaped by its proximity to Lake Nicaragua. Along the way, we dive into the city's layered history—from Spanish colonization to ambitious canal plans that never fully materialized, including the long-debated alternative to the Panama Canal. This episode blends solo travel moments with big-picture history, all set against the backdrop of one of Nicaragua's most beautiful cities.Musical Credits:Momentos by MusicBox and Hello Love by Jasmine J Walker provided by: Slipstream Music Support the showWant to support the podcast? Go to Laura's Patreon site to see photos from the episode, maps of places she talks about and you can become a patron too!Follow the show on instagram or facebook. Buy any of these products that I fully stand behind- and I'll earn a commission. Buy cute sustainable bags at: https://torrain.org/ Use Promo code: TRAVELALONG to get 15% off. Buy matcha at: https://mantramatcha.com/ Use Promo code: TRAVELALONG to get 15% off. Buy sustainably produced coffee: https://www.afueracoffee.com/ Enter promo code: TRAVELALONG for 15% off. Flowers by Cedric Galke x Fachhochschule Dortmund is licensed under a Attribution 4.0 International License.

Why Dec. 25? Why so much Christmas conflict & controversy in Christianity's history? Why is Christmas so important to Christianity? And to America? In this episode, I ask my guest, Dr. Carey Roberts, the following questions: ►Why is Christmas such a grand celebration? What does this tell us about Christianity? ►Did it take a while for Christmas to take a central role in Christianity►What's the difference between recognition and celebration of Christmas►Did Christmas piggyback on existing Roman pagan traditions? ►How did Christmas enter America's culture? If not the Puritans, then which immigrant group introduced Christmas to America? ►Were there any regional differences in the celebration of Christmas?►When did U.S. businesses begin to capitalize on Christmas? ►Would President Grant have witnessed a similar Christmas celebration in Boston and Savannah? ►Would George Washington recognize our Christmas? How about Andrew Jackson? Abraham Lincoln? Teddy Roosevelt? ►What happened to Christmas after WWII? ►Is it a bad thing that non-Christians and/or non-practicing Christians celebrate Christmas? ⁠

"The thought of recurrence is also a psychosocial issue for our patients. They're being monitored very closely for five years, so there's always that thought in the back of their head, 'What if the cancer comes back? What are the next steps? What am I going to do next?' It's really important that we have conversations with patients and their families about where they're at, what we're looking for, and reassure them that we'll be with them during this journey and help them through whatever next steps happen," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer survivorship considerations for nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by December 19, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to survivorship nursing considerations for people with prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 390: Prostate Cancer Treatment Considerations for Nurses Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 201: Which Survivorship Care Model Is Right for Your Patient? Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: APRNs Collaborate With PCPs on Shared Survivorship Care Models Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Here Are the Current Nutrition and Physical Activity Recommendations for Cancer Survivors Nursing Considerations for Prostate Cancer Survivorship Care Regular Physical Activity and Healthy Diet Lower Risk of All-Cause and Cardiac Mortality in Prostate Cancer Survivors Sexual Considerations for Patients With Cancer Sleep Disturbance Is Part of a Behavioral Symptom Cluster in Prostate Cancer Survivors ONS course: Essentials in Survivorship Care for the Advanced Practice Provider Clinical Journal of Oncology Nursing articles: A Patient-Specific, Goal-Oriented Exercise Algorithm for Men Receiving Androgen Deprivation Therapy Incorporating Nurse Navigation to Improve Cancer Survivorship Care Plan Delivery Prostate Cancer: Survivorship Care Case Study, Care Plan, and Commentaries The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: A Qualitative Exploration of Prostate Cancer Survivors Experiencing Psychological Distress: Loss of Self, Function, Connection, and Control Identification of Symptom Profiles in Prostate Cancer Survivors Sleep Hygiene Education, ReadiWatch™ Actigraphy, and Telehealth Cognitive Behavioral Training for Insomnia for People With Prostate Cancer Understanding Men's Experiences With Prostate Cancer Stigma: A Qualitative Study Other ONS resources: Late Effects of Cancer Treatment Huddle Card Survivorship Care Plan Huddle Card Survivorship Learning Library American Cancer Society (ACS): Living as a Prostate Cancer Survivor ACS prostate cancer survivorship studies To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Some of the most common late side effects [are] urinary, bowel, and sexual dysfunction issues. For urinary effects, it can include urgency and frequency, some incontinence, or a weak or slow urine stream that frequently bothers the patient after treatment. Bowel effects can happen such as constipation, diarrhea, or inflammation of the rectum, which can lead to bleeding or mucus discharge. And then erectile dysfunction is another side effect that patients with prostate cancer often deal with and have to work with their physicians on, depending on what they want with that function. Fatigue, lymphedema, and skin changes can also occur after treatment." TS 1:40 "If we can catch [prostate cancer] and take care of it at an early stage, overall survival is about 90%. If the disease is localized, it's 99%. If we can take out the prostate, radiate the prostate, we can do something with that—localized, 99% survival rate. If there's regional metastasis, it's about 90%. And if there's distant metastasis, it's about 30% survival." TS 3:55 "Prostate cancer recurs in about 20%–30% of patients within the first five years of initial treatment. ... There's not a lot of research out there that shows what can reduce risk, but what has been shown to be effective is regular exercise, quitting smoking, and eating a healthy diet. ... It's really important for our patients to understand the importance of having follow-up visits so that we can catch a recurrence quickly instead of waiting years down the road. Prostate cancer is usually a slow-growing disease, so if we can pick it up quickly in those revisits, we can start another treatment for the patient." TS 6:00 "Sexuality is not something many people are comfortable discussing, but we really need to talk with patients and let them know that this is normal. It is normal that you may have some sexual dysfunction. It's normal that you may not feel the way you did before. Talk to us about it, let us know where you're at, let us know what your goals are, because there are a lot of things we can do. There are medications we can use for impedance. There are devices and implants available to help the patient to support them and give them whatever their goal is for their sexuality." TS 9:41 "Providing survivorship care plans are important for these patients—something that can be sent off to everyone else that's caring for that patient. You have your primary care physician, urologist, oncologist, the oncology nurse, maybe a navigator, and [others] who are looking into this patient. So, giving that patient a survivor care plan and putting it with their files to include a summary of the treatment received, because most of the time a patient is not going to remember exactly what they received. A suggested schedule for follow-up exams—so again, if a primary care provider is not used to dealing with a patient with prostate cancer, they have something to go off of. A schedule of other tests they may need in the future including screening for other types of cancer. Are they a smoker? Do they need lung screening? Do they need any other screenings related to types of cancers? And then a list of possible late or long-term side effects." TS 15:16 "I think a lot of people know about the long-term sexual effects, but what we don't really talk about is the effect that it has on the patient's self-image. How they define themselves, how they look, their body image, their self-image. It's really important that we continue to discuss it with patients and make them comfortable when discussing their sexuality and their goals for sexuality. They may be having these self-image issues after treatment that they're just not telling us about and that can affect their quality of life." TS 18:38

Welcome to episode 310 of Grow Your Law Firm, hosted by Ken Hardison. In this episode, Ken is joined by Jake Soffer, Founder and CEO of FirmPilot, an AI-driven marketing platform built to help law firms acquire more clients through intelligent automation and deep market data. Jake brings over a decade of experience in natural language processing and artificial intelligence, rooted in his computer engineering studies at RPI and NYU. Before founding FirmPilot, he built and exited companies in the NLP space and now leads one of the most advanced AI marketing systems in the legal industry—what he calls a "high-performing AI agency in a box." With FirmPilot now supporting more than 120 firms, Jake is at the forefront of how AI, competitive intelligence, and real-time data are reshaping the way legal practices grow. What you'll learn about in this episode: 1. How AI Content Really Works - What differentiates low-quality AI content from high-performing - Why models trained on legal sources outperform generic tools like ChatGPT 2. Using Market Data to Outperform Competitors - Why copying what you see your competitors doing will usually fail - How to analyze deeper signals like backlinks, markup, and behavioral data 3. Domain Authority and Backlinks - What domain authority really measures and how to interpret it - Why quality, consistency, and relevance in link building now outweigh volume 4. Attribution and Tracking in a Multi-Channel World - Why last-touch attribution no longer gives you the full picture - How Google Tag Manager and call-tracking create accurate marketing feedback loops 5. Preparing for the Future of AI Search - How generative engines like ChatGPT and Gemini evaluate legal expertise - Why optimizing for "fanned-out queries" and AI overviews is becoming essential Resources: Website: firmpilot.com LinkedIn: linkedin.com/in/jake-soffer-jd-00797a62 Facebook: facebook.com/p/FirmPilot-100092301576461 Instagram: instagram.com/firmpilot     Additional Resources:    https://www.pilmma.org/the-mastermind-effect https://www.pilmma.org/resources https://www.pilmma.org/mastermind AI for PI Expo:   www.pilmma.org/ai-for-pi-expo

Slay bells ring in 1980s London as Dave and Jon tackle Edmund Purdom et al's Don't Open till Christmas (1984). CW: Violence, gendered violence, problematic portrayals of LGBTIQ+ characters. Copyright © 2025 David Thomas and Jon Dear Availability on disc and streaming: Blu-ray.com Our theme music:Silent Night (Dark Piano Version) by myuu Creative Commons — Attribution 3.0 Unported— CC BY 3.0Free Download/Stream Music promoted by Audio Library Giallo Reading ListLa Dolce Morte: Vernacular Cinema and the Italian Giallo Film by Mikel J. Koven Italian Giallo in Film and Television: A Critical History by Roberto Curti So Deadly, So Perverse: 50 Years of Italian Giallo Films by Troy HowarthVolume 1: 1963-1973Volume 2: 1974-2013Volume 3: Giallo-Style Films From Around the World Mario Bava: All the Colours of the Dark by Tim Lucas Dario Argento: The Man, the Myths & the Magic by Alan Jones All the Colours of Sergio Martino by Kat Ellinger Beyond Terror: The Films of Lucio Fulci by Stephen Thrower Human Beasts: The Films of Paul Naschy by Troy Howarth Italian Horrors: Cannibals, Zombies, Strange Vices and Guilty Pleasures! edited by Allan Bryce Make Them Die Slowly: The Kinetic Cinema of Umberto Lenzi by Troy Howarth

Have you ever looked at a piece of religious art in your local church, a museum, or online and wonder how to interpret its meaning? Join Angela Sealana and her guest, Kathryn Laffrey of KL Art Studio as they discuss how Sacred art can lead us to greater hope and encouragement when we learn how to appreciate its significance. In this episode, you will discover: How did art become so important in Christian tradition? Why is art important for our mission as Christians, including care for the poor and vulnerable? What are the meanings of common sacred art symbols? How can viewing sacred art strengthen our hope? Continue Your Journey: Guest information and helpful resources. * Correction: Pope John Paul II wrote The Jeweller's Shop as Bishop Karol Wojtyła in 1960 during the threat of Communism in Poland, not during his underground theater days as implied by Angela during the discussion. Jewel for the Journey: "Not all are called to be artists in the specific sense of the term. Yet, as Genesis has it, all men and women are entrusted with the task of crafting their own life: in a certain sense, they are to make of it a work of art, a masterpiece." - Pope St. John Paul II Resurrection Stained Glass Window image Attribution, NateBergin, CC BY 4.0 Do you like what you hear? Become a Missionary of Hope by sponsoring a week of Journeys of Hope. Click here to get started. Learn more at https://pilgrimcenterofhope.org/media-and-resources/all-media-series/journeys-of-hope.html Help us spread hope! https://pilgrimcenterofhope.org/support

Find Merch here: https://theirrelevant.org/store Join The El Pochcast Discord here: https://discord.gg/AS8RuMHsxJ Bluesky: @elpochcast.pocho.online Instagram: @elpochcast Email : elpochcast@ gmail.com Text: www.pocho.online El Pochcast is a part of The Irrelevant Podcast Network rapture.mp3 by Vincent Augustus is licensed under a Attribution 4.0 International License. https://creativecommons.org/licenses/by/4.0/ Support El Pochcast by contributing to their tip jar: https://tips.pinecast.com/jar/el-pochcast

Measuring marketing's impact is hard. There's no silver bullet. And if someone tells you there is, they're probably selling you something that only tracks clicks.This week, Elena, Angela, and Rob are joined by Chief Analytics Officer Matt Hultgren to tackle one of marketing's most persistent challenges: measurement. They explore why so many campaigns fail before they even launch, how to balance short-term performance with long-term brand building, and why the best marketers use multiple models to find the truth.Topics covered: [02:00] Why human behavior makes measurement messy[04:00] The planning problem causing measurement failures[06:00] Choosing your North Star metric[08:00] Balancing immediate CAC with long-term brand growth[10:00] Using multiple models to triangulate the truth[13:00] Quantifying TV's halo effect across channels[15:00] Incrementality testing vs MMM vs synthetic controls To learn more, visit marketingarchitects.com/podcast or subscribe to our newsletter at marketingarchitects.com/newsletter.  Resources: 2025 Marketing Architects Report: https://www.marketingarchitects.com/Long-and-Short  Get more research-backed marketing strategies by subscribing to The Marketing Architects on Apple Podcasts, Spotify, or wherever you listen to podcasts. 

It's an episode just absolutely full of fish! Thanks to Arthur, Yuzu, Jayson, Kabir, Nora, Siya, Joel, Elizabeth, Mac, Ryder, Alyx, Dean, and Riley for their suggestions this week! Further reading: Study uncovers mechanics of machete-like 'tail-whipping' in thresher sharks Business end of a sawfish: Giant freshwater stingray! The frilled shark looks like an eel: The frilled shark's teeth: The thresher shark and its whip-like tail [photo by Thomas Alexander - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=50280277]: The Halmahera epaulette shark, looking a little bit like a long skinny koi fish [photo by Mark Erdmann, California Academy of Sciences, Attribution, https://commons.wikimedia.org/w/index.php?curid=30260864]: A mudskipper, which is a fish even though it kind of looks like a weird frog [photo by Heinonlein - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=44502355]: The red-lipped batfish wants a big kiss: The male blue groper is very blue [photo by Andrew Harvey, some rights reserved (CC BY) - https://www.inaturalist.org/photos/62196538, CC BY 4.0, https://commons.wikimedia.org/w/index.php?curid=157789928]: The giant oarfish is very long: Show transcript: Welcome to Strange Animals Podcast. I'm your host, Kate Shaw. This week we have a big fish episode! I mean, it's a big episode about a lot of different fish, not necessarily fish that are big—although some of them sure are! Thanks to Arthur, Yuzu, Jayson, Kabir, Nora, Siya, Joel, Elizabeth, Mac, Ryder, Alyx, Dean, and Riley. I told you this is a big fish episode. Let's jump right in with a fish suggested by Jayson, the sawfish. There are five species of sawfish alive today. The smallest can still grow over 10 feet long, or 3 meters, while the biggest species can grow over 20 feet long, or 6 meters. The largest sawfish ever reliably measured was 24 feet long, or 7.3 meters. The sawfish lives mostly in warm, shallow ocean waters, usually where the bottom is muddy or sandy. It can also tolerate brackish and even freshwater, and will sometimes swim into rivers and live there just fine. The sawfish is a type of ray, and rays are most closely related to sharks. Like sharks, rays have an internal skeleton made of cartilage instead of bone, but they also have bony teeth. You can definitely see the similarity between sharks and sawfish in the body shape, although the sawfish is flattened underneath, which allows it to lie on the ocean floor. There's also another detail that helps you tell a sawfish from most sharks: the rostrum, or snout. It's surprisingly long and studded with teeth on both sides, which makes it look like a saw. The teeth on the sawfish's saw are actual teeth. They're called rostral teeth and the rostrum itself is part of the skull, not a beak or a mouth. It's covered in skin just like the rest of the body. The sawfish's mouth is located underneath the body quite a bit back from the rostrum's base, and the mouth contains a lot of ordinary teeth that aren't very sharp. Since the sawfish has plenty of teeth in its mouth, you may be wondering how and why it also has extra teeth on both sides of its saw. It's because the rostral teeth evolved from dermal denticles. Dermal denticles look like scales but they're literally teeth, they're just not used for eating. Sharks have them too, along with some other fish. In the case of the sawfish, the rostral teeth grow much larger than an ordinary dermal denticle, and stick out sideways. Both the rostrum and the head are packed with electroreceptors that allow the sawfish to sense tiny electrical charges that animals emit as they move. This might mean a school of fish swimming through muddy water, or it might mean a crustacean hiding in the sand. The sawfish sometimes uses its rostrum to dig prey out of the sand, but it also uses it to slash at fish or other animals.

The party wraps up its investigation of Greengripe and makes a controversial deal with an enemy. Meanwhile, Mike needs a recon.WebsiteDiscordTwitterPathfinder Second Edition and the Kingmaker Adventure Path are published by Paizo."Take the Lead" and other featured music were composed by Kevin MacLeod and licensed under Creative Commons by: Attribution 4.0 License.All ambiances were composed by Michael Ghelfi Studios.The Zero Check are committed to providing an inclusive and respectful experience to all listeners, but we also recognize and acknowledge that we are limited by our individual frames of reference. If we misstep, please let us know. Email all feedback to feedback@zerocheckpodcast.com.Thank you for listening to The Zero Check. Send us a text

Episode Notes Even though Jesus would be found in an animal stall the sign they were given was so blatant that they could not miss Jesus when they saw Him. They would know for sure, despite any heavenly sign or imparted Godly knowledge to them, that this babe in swaddling clothes was undeniably Jesus Christ, known also as the Son of God and the Son of Man because of His unique birth. Our Outreach Web site is now closed. Sorry for any inconvenience. Introduction ~ About Us, Who We Are: Episode 1 How-To Be Saved: Episode 2 **** “End Times” and “Benediction” A “Barking Squirrel Production” Copyright: 2018 ~ All Rights Reserved Our Series: “Christmas 2025”: 2025-1202 Episode: 49 Copyright: 2025 TAGS: #Gospel #Christ #Newbirth #Joy #Holiness ---------------------------------------------- The following music was used for this media project: Music: Silent Night - Holy Night by Alexander Nakarada License (CC BY 4.0): https://filmmusic.io/standard-license Artist website: https://www.serpentsoundstudios.com/ Modified by: Pastor John Music: Jingle Jangle Bells by Snoozy Beats License (CC BY 4.0): licensed under a Attribution 4.0 International License. Allowed usage for Personal and commercial use. This music track (or part of it) was generated by A.I. The full track can be heard here: https://freemusicarchive.org/music/snoozy-beats/single/jingle-bells-kinda-day-10/ Edited by: Pastor John This podcast is powered by Pinecast.

In dieser Folge sprechen wir mit Birger Schäfermeier, dem CEO der tradAc (European Trading Academy AG) und Geschäftsführer von Arete Trading, über Trading, Mindset und persönliche Freiheit. Wir gehen der Frage nach, warum so wenige Menschen wirklich profitabel handeln und welche tief verankerten Glaubenssätze viele Deutsche dabei ausbremsen. Birger teilt seine Sicht darauf, was Freiheit eigentlich bedeutet, warum Emotionen beim Traden oft unterschätzt werden – und ob es überhaupt „negative“ Emotionen gibt. Zum Abschluss reden wir über ein Thema, das jeden beschäftigt: Macht Geld wirklich glücklich?

A wealthy British businessman living in colonial Egypt finds his comfortable life begin to unravel when he is haunted by the mysterious sound of footsteps that seem to follow him through the streets at night.This original recording is an audio presentation by Jasper L'Estrange for EnCrypted Horror. “THE STEP” by E.F. Benson, 1931.Supporting my workIf you like, you can donate in the following ways:Patreon: https://www.patreon.com/encryptedpodYouTube channel membership: https://www.youtube.com/c/EnCryptedClassicHorror/joinOne-off donation: https://ko-fi.com/encryptedpodcastYou can now also say THANKS (on YouTube) with a SUPER THANKS!LIKE, COMMENT, SHARE - it all helps the show survive and prosper!If you want to discuss the show, talk business, or have any ideas for stories you'd like to hear in future episodes, contact me: encryptedpod@gmail.com

"I'll go back to the backpack analogy. When your kids come home with a backpack, all of a sudden their homework is not on the desk where it's supposed to be. It's in the kitchen; it kind of spreads all over the place, but it's still in the house. When we give antibody–drug conjugates (ADCs), the chemotherapy does go in, but then it can kind of permeate out of the cell membrane and something right next to it—another cancer cell that might not look exactly like the cancer cell that the chemotherapy was delivered into—is affected and the chemotherapy goes over to that cancer cell and kills it," ONS member Marisha Pasteris, OCN®, office practice nurse in the breast medicine service at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about ADCs in metastatic breast cancer. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Gilead and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 378: Considerations for Adolescent and Young Adult Patients With Metastatic Breast Cancer Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 303: Cancer Symptom Management Basics: Ocular Toxicities ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options Communication Case Study: Talking to Patients About Progressive Metastatic Breast Cancer What Is HER2-Low Breast Cancer? ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin-ejfv Fam-trastuzumab deruxtecan-nxki ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Guide to Breast Care for Oncology Nurses Guide to Cancer Immunotherapy (second edition) ONS courses: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care The Association Between Hormone Receptor Status and End-of-Life Care Among Patients With Metastatic Breast Cancer Oncology Nursing Forum article: Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes ONS huddle cards: Altered Body Image Huddle Card Chemotherapy Huddle Card Targeted Therapy Huddle Card Foundations of Antibody–Drug Conjugate Use in Metastatic Breast Cancer: A Case Study ONS Biomarker Database (refine by breast cancer) ONS Breast Cancer Learning Library American Society of Clinical Oncology (ASCO) homepage Drugs@FDA package inserts National Comprehensive Cancer Network homepage Susan G. Komen metastatic breast cancer page To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "What an ADC is doing is taking the antibody and linking it to a cytotoxic chemotherapy with the idea of delivering it directly into the cell. How I explain this to new nurses or patients is a backpack analogy. If we think of it as a HER2 molecule wearing a chemo backpack, it's going to find the HER2 receptor attached to it and then drop the chemotherapy into the cell via the backpack. Similar to how we come home from work, we open the key to our door, we're carrying all of our items, and then we drop our own personal items in our house." TS 2:30 "The reason that so many patients with metastatic breast cancer are able to receive ADC therapy is because they are targeting two very common antibodies that we see in breast cancer. One is HER2 and the other is trophoblast cell surface antigen 2 (TROP2). These are seen across the board. We see these on triple-negative breast cancers, hormone receptor–positive cancers, and HER2-positive breast cancers. And now we have a new way to talk about HER2, which is a HER2-low. ... Recently, we have found that patients who express low levels of HER2 are able to receive ADC therapy, specifically fam-trastuzumab deruxtecan." TS 4:21 "Another [ADC] that has just been approved is datopotamab deruxtecan. This is another ADC that targets the TROP2 receptor on a cancer cell. This one carries a lot of side effects. I mentioned earlier that you need an ophthalmology clearance because there is a lot of ocular toxicity around this one. We see a lot of blepharitis, conjunctivitis, there can be blurred vision. Another thing we monitor on this one is mucositis. In the package insert, there's a recommendation for using ice chips while receiving the treatment. ... Then in the HER2-positive and HER2-low space is the big one, which is fam-trastuzumab deruxtecan. This was approved in 2019 for the HER2-positive patients, then more recently in the HER2-low [patients]. The big [side effect] with this one is interstitial lung disease." TS 10:11 "Interstitial lung disease is an inflammation or a little bit of fibrosis within the lung that causes an impaired exchange between the oxygen and carbon dioxide. This was seen in the clinical trials, specifically around fam-trastuzumab deruxtecan. During the trials, they had a very small percentage, I think it was 1%, that died due to interstitial lung disease. So, this is a very important side effect for us as nurses to be aware of. It typically presents in patients like a dyspnea. A lot of times, it's like, 'Well, I used to be able to walk my kid to the bus stop, but now when I walk there, I feel really short of breath.' Or 'I've had this dry cough for the past couple weeks and I've tried medications, but haven't had that relieved.' So, we really need to be aware of that because early intervention in interstitial lung disease is key." TS 12:57 "ADCs are toxic drugs. They have the benefit of being targeted, but we know that they carry a lot of side effects. ... Their specificity makes them so wonderful and we've seen amazing responses to these drugs. But also, we want patients to be safe. We want to give these drugs safely. So, we have to assess our patients and make sure that this is an appropriate patient to give this therapy to. I think that's an open conversation that clinicians need to have with patients regarding these drugs." TS 18:08

Of Monsters and Mushrooms, Ch. 12 (book 1 NEW) ep. 809 The Literal Boulder from Indiana Jones NOTE: This is a rewrite of book 1. Originally, 'Of Monsters and Mushrooms' was supposed to be a multi-part short story that transformed halfway through into a novel. This left the plot (and the voice acting, to be honest) lacking. We decided to go back and completely rewrite book one to fix any plot holes and bring the quality in line with the rest of the series. Listen to the new book one playlist here https://talltaletv.com/series-of-monsters-and-mushrooms-new/ or Listen to book one (NEW!) https://talltaletv.com/series-of-monsters-and-mushrooms-new/ Listen to book two http://talltaletv.com/series-of-tyrants-and-teakettles/ Listen to book three http://talltaletv.com/series-of-bandits-and-bad-magic/ Listen to book 3.5 https://talltaletv.com/series-an-interlude-of-intrigue/ Listen to book four https://talltaletv.com/series-of-portals-and-portents/ Listen to book five https://talltaletv.com/series-of-risk-and-relativity/   Listen to the original book one http://talltaletv.com/series-monsters-mushrooms/   ---- Listen Elsewhere ---- YouTube:  https://www.youtube.com/c/TallTaleTV Website: http://www.TallTaleTV.com   ---- Story Submission ---- Got a short story you'd like to submit? Submission guidelines can be found at http://www.TallTaleTV.com   ---- About Tall Tale TV ---- Hi there! My name is Chris Herron and I'm an audiobook narrator. In 2015, I suffered from poor Type 1 diabetes control which lead me to become legally blind for almost a year. The doctors didn't give me much hope, predicting an 80% chance that I would never see again. But I refused to give up and changed my lifestyle drastically. Through sheer willpower (and an amazing eye surgeon) I beat the odds and regained my vision. During that difficult time, I couldn't read or write, which was devastating as they had always been a source of comfort for me since childhood. However, my wife took me to the local library where she read out the titles of audiobooks to me. I selected some of my favorite books, such as the Disc World series, Name of the Wind, Harry Potter, and more, and the audiobooks brought these stories to life in a way I had never experienced before. They helped me through the darkest period of my life and I fell in love with audiobooks. Once I regained my vision, I decided to pursue a career as an audiobook narrator instead of a writer. That's why I created Tall Tale TV, to support aspiring authors in the writing communities that I had grown to love before my ordeal. My goal was to help them promote their work by providing a promotional audio short story that showcases their writing skills to readers. They say the strongest form of advertising is word of mouth, so I offer a platform for readers to share these videos and help spread the word about these talented writers. Please consider sharing these stories with your friends and family to support these amazing authors. Thank you!   ---- legal ---- All stories on Tall Tale TV have been submitted in accordance with the terms of service provided on http://www.talltaletv.com or obtained with permission by the author. All images used on Tall Tale TV are either original or Royalty and Attribution free. Most stock images used are provided by http://www.pixabay.com , https://www.canstockphoto.com/ or created using AI. Image attribution will be declared only when required by the copyright owner. Common Affiliates are: Amazon, Smashwords

Natalia Chappell is the founder of Natalia Chappell & Co, a UK-based consultancy helping luxury and lifestyle brands scale sustainably. Previously, she led marketing for THG's luxury division, working with brands like Coach and Ralph Lauren across price points from hundreds to thousands of pounds.In this episode of DTC Pod, Natalia breaks down what it really takes for US brands to win in the UK—and why so many get it wrong. She shares the full-funnel mistakes she sees premium brands make over and over, why some household US names thrived in Britain while others quietly retreated, and what's actually driving results on Meta right now. She also gets into how to connect with younger consumers who think differently about spending, and why the old playbook of polished content isn't cutting it anymore. Plus, her journey from corporate marketing leader to female founder, and what she wishes more people understood about building a business as a woman.Episode brought to you by StordInteract with other DTC experts and access our monthly fireside chats with industry leaders on DTC Pod Slack.On this episode of DTC Pod, we cover:1. Lessons from high-growth UK e-commerce brands 2. Creating sustainable, holistic marketing strategies3. Using data and analytics to drive channel mix decisions4. Optimizing for paid and organic synergy5. Landing page and website audit best practices6. UGC, influencer, and creator partnership frameworks7. Onboarding and managing creators for conversion and brand fit8. Navigating UK logistics, customs, and local expectations9. How to adapt brand voice and content for UK consumer10. UK cultural moments and how to plan campaigns around them11. Success stories (Drunk Elephant, Ralph Lauren, Coach) and why some US brands flop12. Digital-first approaches to brand building13. Upcoming trends—partnership ads, authentic content, and Gen Z consumers14. Supporting and growing as a female founder in e-commerceTimestamps00:00 Introduction to DTC POD and episode with Natalia Chappell01:18 Natalia's background: fashion, digital marketing, luxury brand experience03:26 Lessons learned building luxury and beauty e-commerce teams05:16 Becoming a female founder and launching Natalia Chappell & Co07:22 The type and scale of brands Natalia's agency works with09:07 Optimizing paid-to-organic mix for sustainable growth12:12 Data, analytics, and the importance of first-party data integrity13:33 Why understanding inventory and offer depth matters before scaling ads16:26 Building a marketing flywheel that feeds itself18:50 Audience segmentation, CRM, and conversion optimization20:08 Attribution modeling and keeping data integrations clean22:29 Organic growth: auditing website, SEO, landing pages, and reviews24:03 Content strategy: authentic UGC, influencers, and the UK market26:58 Equipping creators for conversion, not just reach29:25 Structuring affiliate and creator programs, commissioning vs. flat fees33:01 Logistics: Warehousing, customs, and UK delivery expectations36:54 Adapting voice, copy, and calendar to resonate in the UK38:34 Brand case studies: Drunk Elephant, Coach, Ralph Lauren41:09 Why some US brands struggle in the UK (Forever 21, etc.)44:21 Trends to watch: partnership ads, content authenticity, Gen Z targeting47:25 Where to find and connect with Natalia ChappellShow notes powered by CastmagicPast guests & brands on DTC Pod include Gilt, PopSugar, Glossier, MadeIN, Prose, Bala, P.volve, Ritual, Bite, Oura, Levels, General Mills, Mid Day Squares, Prose, Arrae, Olipop, Ghia, Rosaluna, Form, Uncle Studios & many more.  Additional episodes you might like:• #175 Ariel Vaisbort - How OLIPOP Runs Influencer, Community, & Affiliate Growth• #184 Jake Karls, Midday Squares - Turning Your Brand Into The Influencer With Content• #205 Kasey Stewart: Suckerz- - Powering Your Launch With 300 Million Organic Views• #219 JT Barnett: The TikTok Masterclass For Brands• #223 Lauren Kleinman: The PR & Affiliate Marketing Playbook• ​​​​#243 Kian Golzari - Source & Develop Products Like The World's Best Brands-----Have any questions about the show or topics you'd like us to explore further?Shoot us a DM; we'd love to hear from you.Want the weekly TL;DR of tips delivered to your mailbox?Check out our newsletter here.Projects the DTC Pod team is working on:DTCetc - all our favorite brands on the internetOlivea - the extra virgin olive oil & hydroxytyrosol supplementCastmagic - AI Workspace for ContentFollow us for content, clips, giveaways, & updates!DTCPod InstagramDTCPod TwitterDTCPod TikTokNatalia Chappell - Founder of Natalia Chappell & Co.Blaine Bolus - Co-Founder of CastmagicRamon Berrios - Co-Founder of Castmagic

Find Merch here: https://theirrelevant.org/store Join The El Pochcast Discord here: https://discord.gg/AS8RuMHsxJ Bluesky: @elpochcast.pocho.online Instagram: @elpochcast Email : elpochcast@ gmail.com Text: www.pocho.online El Pochcast is a part of The Irrelevant Podcast Network rapture.mp3 by Vincent Augustus is licensed under a Attribution 4.0 International License. https://creativecommons.org/licenses/by/4.0/ Support El Pochcast by contributing to their tip jar: https://tips.pinecast.com/jar/el-pochcast

The party meets the leader of Greengripe, who accuses them of banditry.WebsiteDiscordTwitterPathfinder Second Edition and the Kingmaker Adventure Path are published by Paizo."Take the Lead" and other featured music were composed by Kevin MacLeod and licensed under Creative Commons by: Attribution 4.0 License.All ambiances were composed by Michael Ghelfi Studios.The Zero Check are committed to providing an inclusive and respectful experience to all listeners, but we also recognize and acknowledge that we are limited by our individual frames of reference. If we misstep, please let us know. Email all feedback to feedback@zerocheckpodcast.com.Thank you for listening to The Zero Check. Send us a text

Subscribe to DTC Newsletter - https://dtcnews.link/signupWhen Sarah Carusona showed up to a DTC event last year, she didn't know it would spark her first client. That client's still with her. Today she runs BA Commerce, where her team drops into brands and drives growth from the inside.For DTC founders scaling from $5M to $20M who need strategy and execution in one package.What you'll learn:Why fractional CMOs often fall short and what brands really need insteadHow to drop in a trained operator who owns growth from top to bottomThe key metrics Sarah watches before touching a budget: contribution margin, AMER, LTV, and the “organic ratio”Why most influencer budgets are broken and what happens when you tie pay to performanceHow to focus your team's time when there's no room for fluffWho this is for:Founders and growth leads who are tired of hiring gaps, agency fluff, and shiny-object distractionsWhat to steal:Rebuild your org chart around execution, not job titlesStructure your influencer deals like paid media, not PRGet obsessed with contribution margin and work backward from thereTimestamps00:00 Why micro-iterations waste ad spend02:00 Sarah's global move and early consulting leap04:00 Building BA Commerce and the growth operator model09:00 How Sarah evaluates brands and sets growth metrics12:00 Creative fatigue, Andromeda, and persona-driven ads15:00 Creator partnerships and a tiered influencer program17:00 Why organic content still drives the biggest wins19:00 Modern Meta account structure and testing philosophy21:00 The biggest mistakes high-growth brands make23:00 Why product quality drives everything in growth25:00 Attribution, incrementality, and Sarah's forecasting model27:00 How Sarah uses AI and where she draws the lineHashtags#dtcpodcast #ecommerce #dtcbrands #mediabuying #growthmarketing #metaads #ugcads #influencermarketing #digitalstrategy #founderstories #shopifybrands #emailmarketing #smsmarketing #marketingpodcast #directtoconsumer Subscribe to DTC Newsletter - https://dtcnews.link/signupAdvertise on DTC - https://dtcnews.link/advertiseWork with Pilothouse - https://dtcnews.link/pilothouseFollow us on Instagram & Twitter - @dtcnewsletterWatch this interview on YouTube - https://dtcnews.link/video

Will Prime Minister Takaichi be a champion for women's rights?

"Working as an oncology infusion nurse, being oncology certified, attending chapter meetings, going to ONS Congress® has really taught me plenty. But being an oncology patient taught me way more. I know firsthand the fears 'you have cancer' brings. Then going through further testing, CT scans, MRIs, genetics, the whole preparation for surgery was something I never considered when I treated a breast cancer patient," ONS member Catherine Parsons, RN, OCN®, told Valerie Burger, MA, MS, RN, OCN®, CPN, member of the ONS 50th anniversary planning committee, during a conversation about her experience being an oncology nurse and cancer survivor. Burger spoke with Parsons and ONS members Margaret Hopkins, MSN, RN, OCN®, HNB-BC, and Afton Dickerson, MSN, AGACNP-BCP, CBCN®, AOCNP®, CGRA, about how cancer survivorship has shaped their careers as oncology nurses and personal lives. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: 50th anniversary series Episode 385: ONS 50th Anniversary: Evolution of Cancer Survivorship Episode 263: Oncology Nursing Storytelling: Renewal Episode 253: The Ethics of Caring for People You Know Personally Episode 187: The Critical Need for Well-Being and Resiliency and How to Practice Episode 91: The Seasons of Survivorship ONS Voice articles: Being a Patient Taught Me How to Be a Better Oncology Nurse by Margaret Hopkins Sharing Our Stories Supports, Celebrates, and Advances the Nursing Profession Our Unified Voices Can Improve Cancer Survivorship Care Why I Truly Understand How Our Patients Hold Onto Hope ONS book: Oncology Nurse Navigation: Delivering Patient-Centered Care Across the Continuum (third edition) ONS course: Essentials in Survivorship Care for the Advanced Practice Provider ONS Nurse Well-Being Learning Library ONS Huddle Cards: Coping Moral Resilience Survivorship Care Connie Henke Yarbro Oncology Nursing History Center To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Parsons: "I thought I knew cancer. I thought I knew the treatment. I thought I knew the side effects. There's so much I didn't know. There's so much behind the scenes before a patient comes and sits in my chair. The stuff that they go through I now can understand. It surprised me how much I didn't know." TS 11:39 Hopkins: "I had been thinking I'm going to be that hero, that I can go to work. I work at night, get 8 am radiation appointments, and go home and go to sleep and wake up and go to work again because everyone said, 'Oh, it's not that bad. Radiation will be okay. You can work.' … But the real challenge for me was I didn't know how to be a patient and a nurse at the same time. And my first radiation treatment, I go in there, and I change into the gown, and then I started cleaning up because I was getting treatment done at the hospital where I worked, and were taught if you see a mess, you clean it. So I was acting like a nurse. And I almost wanted to go help the other patients, but I couldn't because I had to focus on healing." TS 15:36 Dickerson: "What made the difference for me were the nurses who didn't just treat my illness. They treated me as a whole person—my emotions, my feelings. They made me smile. They would hold my hand or just take a moment to really ask, 'Hey, how are you?' And those small, little gestures made me feel worthy, made me feel like a human. I always tell nurses it's not just about the chemo; it's about the connection. Sometimes your presence is the most healing thing that you can offer to your patient." TS 30:52

A Record from The Library at the Center of Everything ep. 808 S. Labrecque is a fantasy author. She previously published "The Killer Doll and the Dollmaker," with Aphelion Webzine and two short stories that can be found on her website: https://slabrecqueauthor.com/ She writes a twice-monthly newsletter and posts on Instagram as she works on publishing her next novel. When she's not writing, Serena can be found hiking, cuddling her cats, and playing D&D with her family.   ---- Listen Elsewhere ---- YouTube:  https://www.youtube.com/c/TallTaleTV Website: http://www.TallTaleTV.com   ---- Story Submission ---- Got a short story you'd like to submit? Submission guidelines can be found at http://www.TallTaleTV.com   ---- About Tall Tale TV ---- Hi there! My name is Chris Herron and I'm an audiobook narrator. In 2015, I suffered from poor Type 1 diabetes control which lead me to become legally blind for almost a year. The doctors didn't give me much hope, predicting an 80% chance that I would never see again. But I refused to give up and changed my lifestyle drastically. Through sheer willpower (and an amazing eye surgeon) I beat the odds and regained my vision. During that difficult time, I couldn't read or write, which was devastating as they had always been a source of comfort for me since childhood. However, my wife took me to the local library where she read out the titles of audiobooks to me. I selected some of my favorite books, such as the Disc World series, Name of the Wind, Harry Potter, and more, and the audiobooks brought these stories to life in a way I had never experienced before. They helped me through the darkest period of my life and I fell in love with audiobooks. Once I regained my vision, I decided to pursue a career as an audiobook narrator instead of a writer. That's why I created Tall Tale TV, to support aspiring authors in the writing communities that I had grown to love before my ordeal. My goal was to help them promote their work by providing a promotional audio short story that showcases their writing skills to readers. They say the strongest form of advertising is word of mouth, so I offer a platform for readers to share these videos and help spread the word about these talented writers. Please consider sharing these stories with your friends and family to support these amazing authors. Thank you!   ---- legal ---- All stories on Tall Tale TV have been submitted in accordance with the terms of service provided on http://www.talltaletv.com or obtained with permission by the author. All images used on Tall Tale TV are either original or Royalty and Attribution free. Most stock images used are provided by http://www.pixabay.com , https://www.canstockphoto.com/ or created using AI. Image attribution will be declared only when required by the copyright owner. Common Affiliates are: Amazon, Smashwords  

In this episode of Wildlife by the Numbers, hosts Matt, Grant, and Randy explore methods for estimating wildlife abundance using both marked and unmarked techniques. They discuss distance sampling, removal sampling, N-mixture models, capture-mark-recapture, and spatial capture-recapture. The conversation emphasizes the importance of robust study design, detection probability, and population closure assumptions in ecological research.Episode Quotes“Marked simply means you have an animal like an ocelot that has spots… so you can identify the same individuals over time based on their coat pattern.”“Distance sampling is a technique in which you take advantage of the fact that things are harder to see or detect at greater distances… and use that to estimate abundance.”“Spatial capture-recapture incorporates where animals were observed and where traps were located… helping produce more precise estimates of abundance and spatial distribution.”Cite this episode: https://doi.org/10.7944/usfws.wbtn.s02ep01DOI Citation Formatter: https://citation.doi.org/Episode music: Shapeshifter by Mr Smith is licensed under an Attribution 4.0 International License. https://creativecommons.org/licenses/by/4.0/https://freemusicarchive.org/music/mr-smith/studio-city/shapeshifter/

Today hosts Ema Sasic and Kevin Schwaller are diving into the world of Oscar nominations. They go through some of the top categories and decide who is in the running for the gold statue. Disclaimer:Copyright notice:(Intro/outro) She's The Greatest Dancer by Ryan Andersen is licensed under a Attribution-NonCommercial License. https://freemusicarchive.org/music/Ryan_Andersen/MORE/Shes_The_Greatest_Dancer?fbclid=IwAR1TDCO9eT6TxmDrTaJr9HRQVk2gUu00cNXeG8oik3avXVEhbSGqsqUfLkoCopyright notice:(Break) Extremely Tik-tok compatible for slow videos by Lundstroem is licensed under a Attribution 4.0 International License. https://freemusicarchive.org/music/lundstroem/the-happiest-songs/extremely-tik-tok-compatible-for-slow-videos/

What happens when AI, blockchain, and decentralized identity merge into a single system for human + machine knowledge? In this Grownlearn episode, host Zorina Dimitrova sits down with Billy Luedtke (ex-EY, ConsenSys, MetaMask) — now founder & CEO of Intuition Systems, the first blockchain network purpose-built for information finance. Billy breaks down: • Why decentralized information is the next frontier beyond DeFi • How Intuition's decentralized knowledge graph lets humans and AI trust the same data • Why tokenized information, decentralized search, and identity will reshape society • What lessons from Ethereum's early days shaped his vision • How Intuition gives users ownership & monetization rights over their data • Why centralized AI + search could lead to a dystopian future — and how we prevent it If you're building in Web3, AI, DeFi, decentralized identity, or data infrastructure, this episode gives a rare look into the architecture and philosophy behind one of the most ambitious projects in the Web3 space. ---------------------------------------------------------------------------------------------------------------------------------------------

They're not helpless babies Find Merch here: https://theirrelevant.org/store Join The El Pochcast Discord here: https://discord.gg/AS8RuMHsxJ Bluesky: @elpochcast.pocho.online Instagram: @elpochcast Email : elpochcast@ gmail.com Text: www.pocho.online El Pochcast is a part of The Irrelevant Podcast Network rapture.mp3 by Vincent Augustus is licensed under a Attribution 4.0 International License. https://creativecommons.org/licenses/by/4.0/ Support El Pochcast by contributing to their tip jar: https://tips.pinecast.com/jar/el-pochcast

In this episode, Brian and Josh discuss attribution theory and its impact on tennis performance. The co-hosts talk about how the interpretation of results makes a significant difference in how tennis players move on and grow from matches that they play. They reviewed the various factors that are included within attribution theory - whether a person attributes their results as internal/external, stable/unstable, and controllable/uncontrollable.To learn more about Josh and Brian's backgrounds and sport psychology businesses, go to TiebreakerPsych.com and PerformanceXtra.com. If you have feedback about the show or questions on the mental game in tennis you can email us at tennisiqpodcast@gmail.com. If you're enjoying the show please rate us on your favorite podcast platform including Apple Podcasts and Spotify and write a review. Don't forget to subscribe on YouTube or your podcast platform of choice (Apple Podcasts, Spotify, etc.) to stay up to date on future episodes.

The traditional linear shopping journey has collapsed. Commerce now happens everywhere, and consumers are navigating this omnimodal reality with unprecedented fluidity.Phillip Jackson and Lindsay Trinkle sit down with Melissa Minkow, Global Director of Retail Strategy and Insights at CI&T, to unpack findings from her Retail Tech Reality Check research. Together, they dissect how different platforms serve distinct purposes in the buyer's journey, why "omnichannel" is more relevant than ever, and what happens when everything becomes shoppable but commerce itself becomes invisible.In this episode, we explore how the expanded digital ecosystem is fundamentally reprogramming how consumers engage with content, community, and commerce. With 74% of US consumers now using AI tools in their path to purchase, brands can no longer control the narrative—instead, they must embed themselves intentionally into customer-led conversations across multiple contexts.Commerce Is Invisible; Context Isn'tKey takeaways:Each social platform serves a distinct purpose: Facebook for purchasing, YouTube for discovery, Reddit for research. Context matters more than channel ubiquity.The invisible transaction wins: TikTok succeeds because it's entertainment-first. The less commerce feels like commerce, the more consumers buy.Attribution is broken: Traditional linear models can't capture circular, contextual journeys. Focus on conversion, repeat purchase, and brand awareness—the only metrics you can trust.Search remains unsolved: Basic functionality like filtering furniture by dimensions is still missing. Data quality and search methodology are foundational competitive advantages.Micro-influencers drive outsized impact: 45 passionate referrals matter more than 45,000 followers. The persona of the referrer (picky, experimental, passionate) outweighs reach.AI will reshape holiday 2025: Gifting anxiety makes AI particularly valuable. Consumers use it to avoid looking stupid and navigate uncertain return processes.In-Show Mentions:Melissa Minkow - Global Director of Retail Strategy and Insights, CI&TCI&T Retail Tech Reality Check ResearchNew Modes ResearchAssociated Links:Check out Future Commerce on YouTubeCheck out Future Commerce+ for exclusive content and save on merch and printSubscribe to Insiders and The Senses to read more about what we are witnessing in the commerce worldListen to our other episodes of Future CommerceHave any questions or comments about the show? Let us know on futurecommerce.com, or reach out to us on Twitter, Facebook, Instagram, or LinkedIn. We love hearing from our listeners! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

  A collection of our conversations with others at the Great Lakes Paranormal Conference this past September. Interviews include owners of the Humbird Hotel Bar & Grill, Ghosts & Us, and 'friends of the show', Katie Skuban and Pat Haberman.  The opening banter includes initial thoughts on the current happenings in the continuing saga of Morgan Geyser.  Sit back and enjoy the conversations, here, on Episode 59 of Badger Bizarre, "The 3rd Annual Halloween (Thanksgiving..?) ParaShare."   The Humbird Hotel Bar & Grill Ghosts and Us US Paranormal Research   Please visit our sponsor:  FrameMakers   Facebook Twitter Website Email us:  badgerbizarre@outlook.com   Opening Trailer: Ed Gein Sound Byte : "Hard Copy" - Paramount Domestic/CBS Televsion Frank Lloyd Wright and Jeffery Dahmer Sound Byte - WISN 12 News - Milwaukee, WI Jeffery Dahmer Quotes: "Inside Edition"  - King World/CBS Television/CBS Media   Attribution for Music: Trailer: Composer: Adam Phillip Zwirchmayr https://www.pond5.com/ Intro: https://pixabay.com/ Outro: Composer: Viacheslav Sarancha  https://www.pond5.com/   Attribution for logo design: Red Claw Scratch Photo  

Cheers to the Host ep. 807 Over eighty-five of Laura Campbell's short stories have appeared in Chilling Crime Stories, Road Kill: Texas Horror by Texas Writers Vol. 6, Reader Beware: A Fear Street Appreciation Anthology, and other publications. Most of Laura's recent works are available on Amazon. Laura's short stories "From the Garden" and "416175" can be heard on Spotify's 'Scare You to Sleep' podcast. When she is not writing, Laura can be found running alongside Houston's bayous or attending live music performances. She is encouraged in her writing by her children, Alexander and Samantha.    ---- Listen Elsewhere ---- YouTube:  https://www.youtube.com/c/TallTaleTV Website: http://www.TallTaleTV.com   ---- Story Submission ---- Got a short story you'd like to submit? Submission guidelines can be found at http://www.TallTaleTV.com   ---- About Tall Tale TV ---- Hi there! My name is Chris Herron and I'm an audiobook narrator. In 2015, I suffered from poor Type 1 diabetes control which lead me to become legally blind for almost a year. The doctors didn't give me much hope, predicting an 80% chance that I would never see again. But I refused to give up and changed my lifestyle drastically. Through sheer willpower (and an amazing eye surgeon) I beat the odds and regained my vision. During that difficult time, I couldn't read or write, which was devastating as they had always been a source of comfort for me since childhood. However, my wife took me to the local library where she read out the titles of audiobooks to me. I selected some of my favorite books, such as the Disc World series, Name of the Wind, Harry Potter, and more, and the audiobooks brought these stories to life in a way I had never experienced before. They helped me through the darkest period of my life and I fell in love with audiobooks. Once I regained my vision, I decided to pursue a career as an audiobook narrator instead of a writer. That's why I created Tall Tale TV, to support aspiring authors in the writing communities that I had grown to love before my ordeal. My goal was to help them promote their work by providing a promotional audio short story that showcases their writing skills to readers. They say the strongest form of advertising is word of mouth, so I offer a platform for readers to share these videos and help spread the word about these talented writers. Please consider sharing these stories with your friends and family to support these amazing authors. Thank you!   ---- legal ---- All stories on Tall Tale TV have been submitted in accordance with the terms of service provided on http://www.talltaletv.com or obtained with permission by the author. All images used on Tall Tale TV are either original or Royalty and Attribution free. Most stock images used are provided by http://www.pixabay.com , https://www.canstockphoto.com/ or created using AI. Image attribution will be declared only when required by the copyright owner. Common Affiliates are: Amazon, Smashwords  

"Antibody–drug conjugates (ADCs) have three basic parts: the antibody part, the cytotoxic chemo, and the linker that connects the two. First, the antibody part binds to the target on the surface of the cell. Antibodies can be designed to bind to proteins with a very high level of specificity. That's what gives it the targeted portion. Then the whole thing gets taken up by the cell and broken down, which releases the chemotherapy part. Some sources will call this the 'payload' or the 'warhead.'  That's the part that's attached to the 'heat-seeking' part, and that's what causes the cell death," Kenneth Tham, PharmD, BCOP, clinical pharmacist in general oncology at the University of Washington Medicine and Fred Hutchinson Cancer Center in Seattle, WA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about antibody–drug conjugates. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 28, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the mechanism of action of antibody–drug conjugates. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 303: Cancer Symptom Management Basics: Ocular Toxicities Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Antibody–Drug Conjugates Join the Best of Two Worlds Into One New Treatment Nursing Management of Adverse Events From Enfortumab Vedotin Therapy for Urothelial Cancer Oncology Nurses' Role in Translating Biomarker Testing Results The Pharmacist's Role in Combination Cancer Treatments ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin Fam-trastuzumab deruxtecan-nxki ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Other ONS resources: Antineoplastic Administration Huddle Card Biomarker Database Chemotherapy Huddle Card Monoclonal Antibodies Huddle Card Association of Cancer Care Centers (ACCC) antibody–drug conjugates page Drugs@FDA Hematology/Oncology Pharmacy Association (HOPA) National Cancer Institute cancer drugs page Network for Collaborative Oncology Development and Advancement (NCODA) clinical resource library ACCC/HOPA/NCODA/ONS Patient Education Sheets website To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The mechanism of action of the chemo itself depends on what agent or what 'warhead' is attached. Generally, [ADCs] have some kind of cytotoxic mechanism related to many of the chemotherapies that we use in practice, without attachment to the antibody. Some of them can be microtubule inhibitors, vinca alkaloids like vincristine. Some of them can be topoisomerase I (TOP1) inhibitors like irinotecan. Some can be alkylating agents that cause DNA breaks. So, again, looking back at the arsenal we have of cytotoxic chemo, these can all be incorporated into the ADCs." TS 5:54 "I want to talk about a case where the biomarker is being tested, but the biomarker isn't the target that you're looking for. One good case of this is a newer agent that was approved called datopotamab deruxtecan. The datopotamab portion is specific to a target called 'trophoblast cell surface antigen 2' (TROP2), which is expressed on the surface of many epithelial cancers. This agent was first approved in hormone receptor-positive, HER2-negative breast cancer, and received accelerated approval in patients with non-small cell lung cancer (NSCLC) with an EGFR mutation. ... The antibody looks for a target, TROP2. But in both of these cases—in the breast cancer and the NSCLC—you're testing for expression of different mutations or lack thereof. You're not looking for expression of TROP2. There's more research that needs to be done about the relationship between TROP2 expression and the presence or absence of these other biomarkers, but until we know more, we're actually testing for biomarkers that aren't the target of the ADC." TS 10:22 "There are common adverse advents to antibodies and chemo in general. Because we have both of these components, we want to watch out for the adverse effects of both of them. Antibodies, as with most proteins, can trigger an immune response or an infusion reaction. So, many ADCs can also cause hypersensitivity or infusion reactions. The rates of that are really variable and depend on the actual antibodies themselves. Then you have the cytotoxic component, the chemotherapy component, which has its own characteristic side effects. So, if we think of general chemo side effects—fatigue, nausea, bone marrow suppression, alopecia—these can [occur] with a lot of ADCs as well." TS 15:34 "The rate of ocular toxicity in [mirvetuximab soravtansine] is quite high. The manufacturer reports that this can occur in up to 60% of patients. With rates so high, the manufacturer recommends a preventive strategy. For this particular agent, [they] recommend patients have required eyecare. ... This ocular toxicity is something we do see in other ADCs that don't have the same target and don't necessarily have the same payload component. For example, tisotumab vedotin and again, datopotamab deruxtecan, can both cause ocular toxicities and both would have required ocular supportive care." TS 20:08 "Overall, I feel like the future is incredibly bright for these agents. There have only been around a dozen therapies approved by the U.S. Food and Drug Administration (FDA) despite this idea—the first agent came out in 2000. So, 25 years later, there are only around a dozen FDA-approved treatments. But there are so many more that are coming through the pipeline. And as we're discovering more biomarkers and developing more specialized antibodies, it's only natural that more ADCs will follow." TS 26:50

Prof. Silverman describes the first Thanksgiving: an accidental feast between frenemies that was never repeated.  How much is our Thanksgiving tradition based on real events that transpired sometime in the fall of 1621 in Plymouth, Massachusetts? And why does it matter anyway?Don't all nations have feel-good traditions that are partly based on facts, but mostly predicated on myths?  Professor David Silverman answers these questions and more. For example, he shares with us that Europeans had been in contact with the Wampanoag Native Americans, who are the "Indians" of our Thanksgiving tradition, since at least 1524. And that the Pilgrims were guided to Plymouth by at least one crew member who touted its advantage - hint: all its native inhabitants had died of disease, leaving houses and fields empty and available for the would-be English settlers. And while the turkey was certainly on the menu, so was eel!   In this episode, Professor Silvermans explains the aftermath of that first Thanksgiving. And by way of follow-up, I ask him to explain why it is that some Native Americans observe a Day of Mourning on Thanksgiving.  Professor Silverman is the author of This Land is Their Land: The Wampanoag Indians, Plymouth Colony, and the Troubled History of Thanksgiving, a 2019 book. Click this link for this book's Amazon page.  Professor Silverman has written several other books about the history of Native Americans, which are listed on his academic homepage is along with his other publications, projects and honors.  Here is the direct link to Professor Silverman's academic homepage: ⁠⁠https://history.columbian.gwu.edu/david-silverman ⁠⁠⁠History of Christmas⁠: ⁠In this interview⁠, Dr. Carey Roberts tells us the real story behind America's celebration of Christmas. I hope you enjoy this episode. Adel, host & producer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠History Behind News⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ podcast & ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠on YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠►⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SUPPORT⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Click here⁠ and join⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠our other supporters in the news peeler community. Thank you.

This is 22 Hours: A Second Look, where we revisit our original season with host Megan Cloherty. In this episode, you'll hear what happened when Megan reached out to Daron Wint in prison. You'll learn just how many prisons he's been transferred to in the last 10 years, why he filed suit while he was inside, and what it takes to communicate with a prisoner in a federal penitentiary.New episodes drop every Tuesday.Original Episode-After Daron Wint's conviction, federal prosecutors press the judge for the harshest possible sentence and, for the first time reveal his history of explosive rage, violent threats and assaults. At Daron's sentencing, emotional statements from the two surviving Savopoulos daughters are read in court. As the last regular episode comes to a close, we reflect back.This episode is written and produced by reporters Megan Cloherty and Jack Moore. Julia Ziegler is the content adviser. "22 Hours: An American Nightmare" is a production of WTOP News in Washington, D.C. All music featured in "22 Hours: An American Nightmare" is licensed through Creative Commons and/or by permission of the artist. We're grateful to all the artists whose music has helped us tell this story. Music for this episode is “Haters Hate” by Ramone Messam; “Beyond the Lows” by The Whole Other and “Spookster” by Wayne Jones, available in the YouTube Audio Library. “Rhythmic Pulse” and “Closing my Eyes for a Moment” by Daniel Birch and “Harbor” by Kai Engel are licensed under Creative Commons by Attribution 4.0 International.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.